Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
NCT ID: NCT00383812
Last Updated: 2006-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2006-05-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV)
2. Secondary objectives
1. To assess the changes in visual acuity
2. To assess the change in lesion characteristics of PCV
* size of PCV
* fluorescein leakage
* foveal thickness
3. To investigate the safety of intravitreal Bevacizumab in patients with PCV
4. To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal Bevacizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCVA of 20/40 to 20/320 (Snellen equivalent)
* Evidence of presumed recent disease progression (blood, growth by FA, or recent VA loss)
Exclusion Criteria
* Media opacity in the study eye that precludes clinical and photographic evaluation
* Intraocular surgery \< 1 month before day 0
* Use of heparin/warfarin within 1 month prior to injection
* Known allergy or hypersensitivity to fluorescein, indocyanine green or povidone iodine
* Contraindication to pupil dilation in either eye
* Any condition which precludes patients' ability to comply with study requirements including completion of the study
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young Hee Yoon, MD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
June-Gone Kim, MD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Sun Young Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Hyewon Chung, MD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bevacizumab for PCV
Identifier Type: -
Identifier Source: org_study_id